

# PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)

NCT07185672

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Tata Memorial Hospital
Enrollment	162 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Male or female, age greater than 18 years
- Histopathological diagnosis of GEP-NET, necessarily satisfying all the the criteria below
- Well differentiated G2 (Ki67 : e3-20%) OR G3 (ki67- greater than 20-55%), OR
- Well-differentiated G1 (<3%) with disease progression in last 6 months
- Positive Ga-68-DOTANOC PET/CT, Krennings score  $\geq 3$
- ... and 4 more (see full listing online)

### Exclusion (10)

- Serum creatinine level of more than 1.6 mg/dl or a creatinine clearance of less than 50 ml/min
- Hemoglobin level of less than 8.0 g per deciliter
- Red blood cell count noty less than 300,000/cubic millimeter White cell count of less than 2000 per cubic millimeter
- Platelet count of less than 75,000 per cubic millimetre
- Total bilirubin level of more than 3 times the upper limit of the normal range
- ... and 5 more (see full listing online)

## Locations (2 total)

---

Tata Memorial Hospital, Mumbai, India, Mumbai, Maharashtra, India  
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Navi Mumbai, Maharashtra, India

---

<https://clinicaltrials.gov/study/NCT07185672>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.